Ketamine for Depression: Evidence, Challenges and Promise

Overview

Journal World Psychiatry

Specialty Psychiatry

Date 2015 Sep 27

PMID 26407791

Citations 21

Authors

Carlos A Zarate Jr

Mark J Niciu

Affiliations

Soon will be listed here.

Citing Articles

Expert recommendations for Germany's integration of psychedelic-assisted therapy.

Perez Rosal S, La Torre J, Birnkammer S, Chernoloz O, Williams M, Faber S BMC Med Educ. 2024; 24(1):1202.

PMID: 39443907 PMC: 11515625. DOI: 10.1186/s12909-024-06141-3.

Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach.

Wolfson P, Vaid G Front Psychiatry. 2024; 15:1209419.

PMID: 38362026 PMC: 10867319. DOI: 10.3389/fpsyt.2024.1209419.

Sense of agency and its disturbances: A systematic review targeting the intentional binding effect in neuropsychiatric disorders.

Moccia L, Di Luzio M, Conte E, Modica M, Ambrosecchia M, Ardizzi M Psychiatry Clin Neurosci. 2023; 78(1):3-18.

PMID: 37755315 PMC: 11488622. DOI: 10.1111/pcn.13601.

Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report.

Joseph B, Nunez N, Kung S, Vande Voort J, Pazdernik V, Schak K Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631079 PMC: 10459873. DOI: 10.3390/ph16081164.

The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review.

Doss M, de Wit H, Gallo D Neurosci Biobehav Rev. 2023; 150:105188.

PMID: 37085021 PMC: 10247427. DOI: 10.1016/j.neubiorev.2023.105188.

References

Maeng S, Zarate Jr C, Du J, Schloesser R, McCammon J, Chen G . Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2007; 63(4):349-52. DOI: 10.1016/j.biopsych.2007.05.028. View

Rasmussen K, Lineberry T, Galardy C, Kung S, Lapid M, Palmer B . Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013; 27(5):444-50. DOI: 10.1177/0269881113478283. View

Niciu M, Luckenbaugh D, Ionescu D, Guevara S, Machado-Vieira R, Richards E . Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014; 75(5):e417-23. PMC: 4310499. DOI: 10.4088/JCP.13m08698. View

Moghaddam B, Adams B, Verma A, Daly D . Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997; 17(8):2921-7. PMC: 6573099. View

Price R, Iosifescu D, Murrough J, Chang L, Al Jurdi R, Iqbal S . Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014; 31(4):335-43. PMC: 4112410. DOI: 10.1002/da.22253. View

Murrough J, Perez A, Pillemer S, Stern J, Parides M, Aan Het Rot M . Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2012; 74(4):250-6. PMC: 3725185. DOI: 10.1016/j.biopsych.2012.06.022. View

Lai R, Katalinic N, Glue P, Somogyi A, Mitchell P, Leyden J . Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 2014; 15(7):579-84. DOI: 10.3109/15622975.2014.922697. View

Niciu M, Luckenbaugh D, Ionescu D, Mathews D, Richards E, Zarate Jr C . Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry. 2013; 74(10):e23-4. PMC: 3805682. DOI: 10.1016/j.biopsych.2013.01.038. View

Beurel E, Song L, Jope R . Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011; 16(11):1068-70. PMC: 3200424. DOI: 10.1038/mp.2011.47. View

10.

Diamond P, Farmery A, Atkinson S, Haldar J, Williams N, Cowen P . Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014; 28(6):536-44. DOI: 10.1177/0269881114527361. View

11.

Brachman R, McGowan J, Perusini J, Lim S, Pham T, Faye C . Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior. Biol Psychiatry. 2015; 79(9):776-786. PMC: 4633406. DOI: 10.1016/j.biopsych.2015.04.022. View

12.

Kantrowitz J, Halberstam B, Gangwisch J . Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry. 2015; 76(6):737-8. DOI: 10.4088/JCP.14l09527. View

13.

Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L . Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol. 2012; 698(1-3):228-34. PMC: 3534778. DOI: 10.1016/j.ejphar.2012.11.023. View

14.

Zarate Jr C, Mathews D, Furey M . Human biomarkers of rapid antidepressant effects. Biol Psychiatry. 2013; 73(12):1142-55. PMC: 3672383. DOI: 10.1016/j.biopsych.2012.11.031. View

15.

Yilmaz A, Schulz D, Aksoy A, Canbeyli R . Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 2002; 71(1-2):341-4. DOI: 10.1016/s0091-3057(01)00693-1. View

16.

Li N, Lee B, Liu R, Banasr M, Dwyer J, Iwata M . mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329(5994):959-64. PMC: 3116441. DOI: 10.1126/science.1190287. View

17.

Zarate Jr C, Brutsche N, Laje G, Luckenbaugh D, Venkata S, Ramamoorthy A . Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012; 72(4):331-8. PMC: 3442255. DOI: 10.1016/j.biopsych.2012.03.004. View

18.

Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D . Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4):351-4. DOI: 10.1016/s0006-3223(99)00230-9. View

19.

Niciu M, Henter I, Luckenbaugh D, Zarate Jr C, Charney D . Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol. 2014; 54:119-39. PMC: 4089991. DOI: 10.1146/annurev-pharmtox-011613-135950. View

20.

Zhang G, Liu W, Qiu L, Guo J, Wang X, Sun H . Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects. Eur Psychiatry. 2015; 30(4):504-10. DOI: 10.1016/j.eurpsy.2014.11.007. View